Phaseline

Targets › MAGEA4

MAGEA4 (Melanoma-associated antigen 4): drug programs, companies and trials

6 programs from 6 companies in 7 trials: 6 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Regulates cell proliferation through the inhibition of cell cycle arrest at the G1 phase. Also negatively regulates p53-mediated apoptosis. (UniProt, P43358)

Open in Phaseline: the race on MAGEA4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
USWM CTAfamitresgene Autoleucel
Melanoma-associated antigen 4 binding agent
MAGEA4Phase 2Synovial SarcomaApr 2038
CDR-LifeCDR404
T-cell engaging bispecific antibody targeting MAGE-A4
MAGEA4Phase 1Select Advanced Solid TumorsDec 2026
Zelluna ImmunotherapyZI-MA4-1
Allogeneic TCR-engineered NK cells targeting MAGE-A4
MAGEA4Phase 1Ovarian CancerDec 2028
Peking UniversityTCR-MAGE-A4 T-Cells
MAGE-A4-directed T cell receptor-engineered T cells
MAGEA4Phase 1Advanced Solid TumorDec 2028
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityTCR-T cells targeting MAGE-A4
TCR-engineered T cells targeting MAGE-A4, a cancer-testis antigen
MAGEA4Phase 1Advanced Mesenchymal MalignanciesDec 2029
PDC*line Pharma SASPDC*lung01
Dendritic cell vaccine loaded with synthetic peptides from lung tumor antigens (NY-ESO-1,
PRAME, MAGEA3, MAGEA4Phase 1Non Small Cell Lung Cancer–

Conditions

Synovial Sarcoma (2) Ovarian Cancer (1) Non Small Cell Lung Cancer (1) Advanced Solid Tumor (1) Select Advanced Solid Tumors (1) Advanced Mesenchymal Malignancies (1)

Modalities

other (3), mixed (2), protein or peptide (1)

Companies

Zelluna Immunotherapy (1) PDC*line Pharma SAS (1) Peking University (1) CDR-Life (1) USWM CT (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)

Related targets

PRAME (1) MAGEA3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.